Eledon Pharma Appoints New CMO, Director
Ticker: ELDN · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $600 million, $6 million, $15 million, $1.5 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-appointment, personnel
TL;DR
Eledon Pharma brings in a new CMO and a new board member, potentially signaling a new phase for the company.
AI Summary
Eledon Pharmaceuticals, Inc. announced on December 16, 2024, the appointment of Dr. Jonathan T. Hunt as Chief Medical Officer and the election of Dr. David M. Epstein to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Hunt's new role.
Why It Matters
These executive changes and board additions can signal strategic shifts or new directions for the company's medical and governance strategies.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan T. Hunt (person) — Appointed Chief Medical Officer
- Dr. David M. Epstein (person) — Elected to Board of Directors
- December 16, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan T. Hunt has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. David M. Epstein has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated December 16, 2024.
What is Eledon Pharmaceuticals, Inc.'s state of incorporation?
Eledon Pharmaceuticals, Inc. is incorporated in Delaware.
What are the main items reported in this 8-K filing?
This filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-20 08:00:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market
- $600 million — the market value of the Company exceeds $600 million. The Performance Bonus payment threshol
- $6 million — ormance Bonus payment threshold remains $6 million at a $600 million market value and incr
- $15 million — and increases up to an amended maximum $15 million bonus payable at a $1.5 billion market
- $1.5 billion — maximum $15 million bonus payable at a $1.5 billion market value using linear interpolation
Filing Documents
- eldn-20241216.htm (8-K) — 38KB
- 0000950170-24-138782.txt ( ) — 148KB
- eldn-20241216.xsd (EX-101.SCH) — 24KB
- eldn-20241216_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit is being filed or furnished as part of this report: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Eledon Pharmaceuticals Date: December 20, 2024 By: /s/ David-Alexandre C. Gros, M.D. Name: David-Alexandre C. Gros, M.D. Title: Chief Executive Officer